TABLE II.
Summary of frequent supportive therapies
| Therapy | Patient group [n (%)] | ||
|---|---|---|---|
|
| |||
| CLL (n=16) | iNHL (n=74) | Overall (n=90) | |
| Any | 15 (93.8) | 72 (97.3) | 87 (96.7) |
| Ondansetron | 11 (68.8) | 47 (63.5) | 58 (64.4) |
| Dexamethasone | 4 (25.0) | 33 (44.6) | 37 (41.1) |
| Prochlorperazine | 6 (37.5) | 23 (31.1) | 29 (32.2) |
| Acetaminophen | 6 (37.5) | 19 (25.7) | 25 (27.8) |
| Filgrastim | 5 (31.3) | 20 (27.0) | 25 (27.8) |
| Allopurinol | 11 (68.8) | 11 (14.9) | 22 (24.4) |
| GM-CSF | 0 (0) | 2 (2.7) | 2 (2.2) |
| Blood-related therapy | |||
| Concentrated RBCs | 1 (6.3) | 12 (16.2) | 13 (14.4) |
| RBCs | 1 (6.3) | 4 (5.4) | 5 (5.6) |
| Epoetin alfa | 2 (12.5) | 2 (2.7) | 4 (4.4) |
| Platelets | 1 (6.3) | 3 (4.1) | 4 (4.4) |
| Whole blood | 1 (6.3) | 1 (1.4) | 2 (2.2) |
| Darbepoetin alfa | 0 (0) | 2 (2.7) | 2 (2.2) |
CLL = chronic lymphocytic leukemia; GM-CSF = granulocyte-macrophage colony-stimulating factor; iNHL = indolent non-Hodgkin lymphoma; RBCs = red blood cells.